Nature Communications (Sep 2019)

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity

  • Wenyan Fu,
  • Changhai Lei,
  • Shuowu Liu,
  • Yingshu Cui,
  • Chuqi Wang,
  • Kewen Qian,
  • Tian Li,
  • Yafeng Shen,
  • Xiaoyan Fan,
  • Fangxing Lin,
  • Min Ding,
  • Mingzhu Pan,
  • Xuting Ye,
  • Yongji Yang,
  • Shi Hu

DOI
https://doi.org/10.1038/s41467-019-12321-3
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 12

Abstract

Read online

Genetically engineered T cells expressing a chimeric antigen receptor (CAR-T cells) are a promising new treatment for cancer, but are associated with unique toxicities. Here, the authors test CAR-T-cell-derived exosomes as a surrogate for CAR-T cells and show that they can elicit a potent antitumour immune response in preclinical models of breast cancer with reduced signs of cytokine release syndrome compared with CAR-T therapy.